Haploidentical hematopoietic stem cell transplantation using low-dose alemtuzumab is effective for standard-risk hematological malignancies
Shinichi Kako(Jichi Medical University), Mrinal M. Patnaik(Mayo Clinic), Masaharu Tamaki(Jichi Medical University), Yuhei Nakamura(Jichi Medical University), Yoshinobu Kanda(Jichi Medical University), Ayumi Gomyo(Jichi Medical University), Junko Takeshita(University of Pennsylvania), Kazuya Sato(Asahikawa Medical College Hospital), Hideki Nakasone(Jichi Medical University), Mohamad Bassam Sonbol(WinnMed), Kento Umino(Jichi Medical University), Yael Kusne(WinnMed), Daisuke Minakata(Jichi Medical University), Kaoru Hatano(Jichi Medical University), Chihiro Yamamoto(Jichi Medical University), Shin‐ichiro Kawaguchi(Jichi Medical University), Nozomu Yoshino(Jichi Medical University), Machiko Kusuda(Jichi Medical University), Þorvarður R. Hálfdánarson(Mayo Clinic), Shin-ichiro Fujiwara(Jichi Medical University), Shun-ichi Kimura(Jichi Medical University), Kazuki Hyodo(Jichi Medical University), Masahiro Ashizawa(Jichi Medical University), Masakatsu Kawamura(Jichi Medical University)
Cited by 0
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Psoriasis and comorbid diseases
|Journal of the American Academy of Dermatology|2017|1.1k
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
Inherited antithrombin deficiency: a review
|Haemophilia|2008|396